ADMA — ADMA BIOLOGICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1368514 ·
Last close
$9.55
Market Cap
$2.14B
52W High
$10.35
52W Low
$7.45
ADV30
2,499,760
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 124,395,000 | 86,277,000 | 52,445,000 | 37,822,000 | 684,210,000 | 136,020,000 | 276,002,000 |
| Mar 2026 | 114,493,000 | 80,750,000 | 50,294,000 | 45,328,000 | 665,184,000 | 138,153,000 | 274,859,000 |
| Dec 2025 | 139,163,000 | 88,816,000 | 62,751,000 | 49,379,000 | 624,242,000 | 87,630,000 | 146,922,000 |
| Sep 2025 | 134,224,000 | 75,626,000 | 51,012,000 | 36,428,000 | 568,687,000 | 61,385,000 | 137,501,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$136,720,000
Investing CF
$-14,496,000
Financing CF
$-76,489,000
CapEx
$-20,496,000
Dividends Paid
—
Buybacks
$-187,185,000
EPS Diluted TTM
$0.70
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-78,503,000
Inventory
$239,313,000
Receivables
$138,231,000
ST Investments
—
EBIT TTM
$225,299,000
Pretax Income TTM
$216,474,000
Interest Exp TTM
$8,825,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$512,275,008
EBITDA
$224,192,992
Free Cash Flow
$54,755,376
Enterprise Value
$43,886,600,192
Total Cash
$55,921,152,000
Total Debt
$97,668,702,208
Shares Out
223,984,680
Trailing EPS
$0.68
Book Value
$1.81
ROE
41.9%
ROA
21.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 510,173,000 | 191,443,000 | 146,930,000 | 624,242,000 | 146,922,000 | — | 50,396,000 |
| Dec 2024 | 426,454,000 | 138,983,000 | 197,673,000 | 488,678,000 | 139,660,000 | — | 118,672,000 |
| Dec 2023 | 258,215,000 | 21,632,000 | -28,239,000 | 329,182,000 | 193,976,000 | — | 8,800,000 |
| Dec 2022 | 154,080,000 | -39,365,000 | -65,904,000 | 348,461,000 | 196,487,000 | — | -59,508,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.98
Max Pain — expiry 2026-11-20
max pain strike: $10.00 · spot: $9.64 · call oi: 22,484 · put oi: 9,263
Expected Move to 2026-11-20:
±$2.12
(22.06%) —
implied range
$7.51 –
$11.76
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MESO | MESOBLAST LTD | $2.16B | $16.64 | — |
| VCEL | Vericel Corp | $2.17B | $42.30 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.18B | $46.67 | — |
| KOD | Kodiak Sciences Inc. | $2.34B | $37.22 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.95B | $5.97 | — |
News headlines (Yahoo Finance, 1h cache)
ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ...
2026-08-06 05:09 · Yahoo
ADMA Biologics Q2 Earnings Call Highlights
2026-08-05 22:03 · Yahoo
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
2026-07-31 21:45 · Yahoo
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
2026-07-29 13:30 · Yahoo
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
2026-07-27 21:50 · Yahoo
ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations
2026-07-15 18:13 · Yahoo
ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run
2026-07-15 07:16 · Yahoo
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
2026-07-13 21:50 · Yahoo
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
2026-07-13 13:30 · Yahoo
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
2026-07-08 18:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.